On September 20, 2023 OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) reported that scientific updates in presentations selected for European and American conferences: at the 7th International Cancer Immunotherapy (CICON) Conference in Milan, Italy (September 20 – 23), at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 38th Annual Meeting in San Diego, CA, US (November 1 – 5) and at the 15th Annual Protein & Antibody Engineering Summit (PEGS) Europe Summit in Lisbon, Portugal (November 14 – 16) (Press release, OSE Immunotherapeutics, SEP 20, 2023, View Source [SID1234635300]). The communications will feature the latest progress on the Company’s research programs in immuno-oncology, namely CLEC-1 (novel myeloid immune checkpoint), CYTOMASK, a new and innovative CIS-demasking cytokine linker technology, BiCKI-IL-7 (bifunctional therapy targeting PD-1 and IL-7), and Tedopi (T-cell epitope-based cancer vaccine).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Nicolas Poirier, Chief Executive Officer of OSE Immunotherapeutics, comments: "OSE will be presenting 9 communications at upcoming leading international scientific conferences. We are proud of the achievements from our researcher teams on the advancement of our innovative programmes. We are committed to progressing those programmes with the most relevant academic and/or pharma partners to further clinical stage studies and ultimately bring breakthrough immunotherapies to patients with high unmet needs."

DETAILS OF THE OSE IMMUNOTHERAPEUTICS NEXT PRESENTATION:

CICON23
Seventh "International Cancer Immunotherapy Conference (CIMT) (Free CIMT Whitepaper): Translating Science into Survival"
SEPTEMBER 20-23, 2023 – MILAN, ITALY

NUMBER

TITLE

SESSION

FIRST AUTHOR

P269

ANTAGONIST ANTIBODIES INHIBITING THE BINDING OF MYELOID CHECKPOINT CLEC-1 TO NOVEL ENDOGENOUS LIGANDS DEMONSTRATE HIGH ANTI-TUMOR EFFICACIES IN HUMANIZED PRECLINICAL MODELS

POSTER SESSION B
Friday, Sept. 22

Irène BACELLI

P270

CIS-DEMASKING CYTOKINE LINKER TECHNOLOGY ALLOWS SELECTIVE CYTOKINE DELIVERY TO ACTIVATED IMMUNE CELLS WHILE SPARING OTHERS AND PERIPHERAL TOXICITY

POSTER SESSION A
Thursday, Sept. 21

Caroline MARY

P271

ANTI-PD-1/IL-7V IMMUNOCYTOKINE FAVORS PROLIFERATION & SURVIVAL OF TCF1+ STEM LIKE MEMORY T CELLS ANDA DURABLE IN VIVO EFFICACY IN MONOTHERAPY OR USING COMBINATORIAL STRATEGY

POSTER SESSION B
Friday, Sept. 22

Aurore MORELLO